Primer Informe del Comité de Anemia en Pacientes en Hemodiálisis Crónica de la Sociedad Latinoamericana de Nefrología e Hipertensión (SLANH)

Carlini, Raúl; Carlini, Raul; Obrador, Gregorio; Campistrús, Nieves; Andrade, Liliana; Chifflet, Liliana; Bregman, Rachel; Locatelli, Alberto; Correa-Rotter, Ricardo; Poblete, Hugo

doi:10.3265/Nefrologia.pre2013.Oct.12234

Article information

Antecedentes: La anemia representa una complicación frecuente en pacientes con enfermedad renal crónica. En Latinoamérica (LA) la prevalencia y características de la anemia en pacientes en hemodiálisis (HD) no ha sido bien estudiada. Objetivo: Evaluar los resultados del primer registro de anemia del Comité de Anemia de la Sociedad Latinoamericana de Nefrología e Hipertensión. Métodos: Esta es una encuesta multinacional, voluntaria, que recolectó datos sobre el tratamiento de la anemia en pacientes en HD de unidades independientes en LA entre septiembre de 2009 y marzo de 2010. Para el análisis estadístico se utilizaron los siguientes métodos: t-test, ANOVA, chi2 y el análisis de regresión logística multivariante. Resultados: La encuesta fue respondida por 134 unidades de HD de 16 países, recibiéndose datos de 9025 pacientes. Las medias ± desviación estándar de Hb, ferritina y del índice de saturación de transferrina (IST) fueron respectivamente: 10,5 ± 1,8 g/dl, 570 ± 539 µg/l y 29,8 % ± 15. Se administró agentes estimulantes de la eritropoyesis (AEE) al 84,3 % de los pacientes y hierro intravenoso (FeIV) al 68,3 %. Solamente el 32,7 % de los pacientes tuvieron una Hb blanco de 10,5-12,0 g/dl. En pacientes con Hb < 10,5 g/dl, el 85,2 % estaban recibiendo AEE y un 68 % FeIV. Las variables independientes asociadas con nivel Hb < 10,5 g/dl fueron: género femenino, IST < 25 % y edad < 50 años. En la muestra de pacientes analizada, a pesar del amplio uso de los AEE y FeIV, casi la mitad de los pacientes no alcanzó la Hb blanco.

Palabras clave:

Encuesta

Palabras clave:

Hemodiálisis

Palabras clave:

Latinoamérica

Palabras clave:

Anemia

Background: Anemia almost invariably occurs in patients with chronic kidney disease. Limited data are available regarding anemia management in Latin American (LA) hemodialysis (HD) patients. Objective: To evaluate the results of the first anemia survey of the Anemia Committee of the SLANH. Methods: This is a multinational, voluntary survey that collected anemia management data from adult HD patients from independent, non-chain owned HD units, between 09/2009 and 03/2010. T-test, ANOVA, chi-square test and multivariate logistic regression were used for statistical analysis. Results: The survey received responses from 134 HD units of 16 countries providing data from 9,025 patients. Mean values of Hb, ferritin, and transferrin saturation (TSAT) were 10.5±1.8g/dL, 570±539µg/l, and 29.8±15%, respectively. Only 32.7% of patients were within the Hb target of 10.5-12.0g/dL (46.3% were below and 21.1% above). Erythropoietin-stimulating agents (ESAs) were administered to 84.3% patients and 68.3% received intravenous iron (IV). Iron deficiency (TSAT≤20%) was present in 27.5% patients and among those receiving erythropoietin, 47% did not achieve Hb target. The independent variables associated with the lowest Hb level (<10.5g/dL) were: female gender, TSAT¿25% and age<50 years. Conclusions: According to these results, nearly half of LA chronic HD patients did not achieve the recommended Hb target despite wide use of ESAs and IV iron.

Keywords:

Survey

Keywords:

Hemodialysis

Keywords:

Latin America

Keywords:

Anemia

Full text is only aviable in PDF

Bibliografía

[1]

Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. for the CHOIR Investigators. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. N Engl J Med 2006;355:2085-98. [Pubmed]

[2]

Drüeke TB, Locatelli F, Clyne N, Eckardt K-U, Macdougall IC, Tsakiris D, et al. for the CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-84. [Pubmed]

[3]

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU et al.; TREAT Investigators. A trial of darbepoetinalfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361(21):2019-32. [Pubmed]

[4]

Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 2012;82:235-41. [Pubmed]

[5]

KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease, 2007 update of hemoglobin target. Am J Kidney Dis 2007;50(3):471-530. [Pubmed]

[6]

Locatelli F, Covic A, Eckardt K-U, Wiecek A, Vanholder R, on behalf of the ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009;24:348-54. [Pubmed]

[7]

Carlini R, Campistrús N, Andrade L, Bregman R, Chifflet L, Correa-Rotter R, et al. Recommendations for the clinical practice of the Latino American Society of Nephrology and Hypertension (SLANH) for the treatment of anemia in patients with chronic renal disease (RPCA-ERC/SLANH). Nefrología Latinoamericana 2009;13:1-30.

[8]

KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012;(2):S299-310.

[9]

Cusumano AM, Gonzalez Bedat MC, García-García G, Maury Fernandez S, Lugon JR, Poblete BH, et al. Latin American Dialysis and Renal Transplant Registry: 2008 Report (data 2006). Clin Nephrol 2010;74 Suppl 1:S3-8.

[10]

Sesso R, Lopes AA, Thomé FS, Bevilacqua JL, Romão JE Junior, Lugon J. Brazilian Dialysis Census Report 2008. J Bras Nefrol 2008;30(4):233-8.

[11]

Gurgel TC, Cherchiglia ML, Acurcio F de A, Szuster DA, Campos DA, Gomes IC, et al. Erythropoietin use by incident HD patients in the Brazilian Unified National Health System, 2002-2003. Cad Saude Publica 2012;28(5):856-68.

[12]

González C, Ferreiro A, Schwedt E, Pinato M. 2009 Uruguayan Register Dialysis. Available at: http://www.nefrouruguay.com/

[13]

Poblete H. Chilenan Nephrology Society. Dialysis Register 2010. Available at: http://www.nefro.cl/registros/registro-de-hemodialisis.html

[14]

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010;14(3):240-75. [Pubmed]

[15]

National Institute for Health and Clinical Excellence (NICE). Anaemia management in people with chronic kidney disease. (CG114). 2011. Available at: http://guidance.nice.org.uk/CG114

[16]

Gilg J, Webb L, Feest T, Fogarty D. UK Renal Registry 13th Annual Report (December 2010): Chapter 9, haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2009: national and center-specific analyses. Nephron Clin Pract 2011;119 Suppl 2:c149-77. [Pubmed]

[17]

US Renal Data System, USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2012. Available at: http://www.usrds.org/atlas.aspxcion

[18]

Hasegawa T, Bragg-Gresham JL, Pisoni RL, Robinson BM, Fukuhara S, Akiba T, et al. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney Int 2011;79(3):340-6. [Pubmed]

[19]

Bamgbola OF. Pattern of resistance to erythropoietin stimulating agents in chronic kidney disease. Kidney Int 2011;80(5):464-74. [Pubmed]

[20]

Elliot J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis 2009;16(2):94-100. [Pubmed]

Indexed in:

Follow us:

Indexed in:

Follow us:

Subscribe to our newsletter